Celgene (CELG) Added to BofA/Merrill Lynch US 1 List
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Celgene (CELG) Revlimid Estimates, PT Lifted at Nomura
October 24, 2014 9:48 AM EDTNomura Securities analyst Ian Somaiya reiterated a Buy and Top Pick rating while boosting his price target on Celgene (NASDAQ: CELG) to $136.00 (from $124.00) following results.
Somaiya commented, "We are increasing our Revlimid estimates and TP to $136, from $124, as we see continued strength in Revlimid sales heading... More
Celgene (CELG) Price Target Raised to $134 at Deutsche Bank
October 24, 2014 9:07 AM EDTDeutsche Bank maintained a Buy rating on Celgene (NASDAQ: CELG) and raised its price target to $134.00 (from $115.00). Analyst Robyn Karnauskas said Celgene was emerging as top pick for 2015.
"The focus of the 3Q call was the strong Otezla launch, and the pipeline,... More
